Literature DB >> 23180276

The central theme of Parkinson's disease: α-synuclein.

Mehmet Ozansoy1, A Nazli Başak.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder, defined by the presence of resting tremor, muscular rigidity, bradykinesia, and postural instability. PD is characterized by the progressive loss of dopaminergic neurons within the substantia nigra pars compacta of the midbrain. The neuropathological hallmark of the disease is the presence of intracytoplasmic inclusions, called Lewy bodies (LBs) and Lewy neurites (LNs), containing α-synuclein, a small protein which is widely expressed in the brain. The α-synuclein gene, SNCA, is located on chromosome 4q22.1; SNCA-linked PD shows an autosomal dominant inheritance pattern with a relatively early onset age, and it usually progresses rapidly. Three missense mutations, A53T, A30P, and E46K, in addition to gene multiplications of the SNCA have been described so far. Although it is clear that LBs and LNs contain mainly the α-synuclein protein, the mechanism(s) which leads α-synuclein to accumulate needs to be elucidated. The primary question in the molecular pathology of PD is how wild-type α-synuclein aggregates in PD, and which interacting partner(s) plays role(s) in the aggregation process. It is known that dopamine synthesis is a stressfull event, and α-synuclein expression somehow affects the dopamine synthesis. The aberrant interactions of α-synuclein with the proteins in the dopamine synthesis pathway may cause disturbances in cellular mechanisms. The normal physiological folding state of α-synuclein is also important for the understanding of pathological aggregates. Recent studies on the α-synuclein protein and genome-wide association studies of the α-synuclein gene show that PD has a strong genetic component, and both familial and idiopathic PD have a common denominator, α-synuclein, at the molecular level. It is clear that the disease process in Parkinson's disease, as in other neurodegenerative disorders, is very complicated; there can be several different molecular pathways which are responsible for diverse and possibly also unrelated functions inside the neuron, playing roles in PD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180276     DOI: 10.1007/s12035-012-8369-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  29 in total

1.  Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death.

Authors:  James T Lee; Tiffany C Wheeler; Lian Li; Lih-Shen Chin
Journal:  Hum Mol Genet       Date:  2007-12-07       Impact factor: 6.150

Review 2.  Milestones in PD genetics.

Authors:  Thomas Gasser; John Hardy; Yoshikuni Mizuno
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

3.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.

Authors:  Jin Xu; Shyan-Yuan Kao; Frank J S Lee; Weihong Song; Lee-Way Jin; Bruce A Yankner
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

5.  Initiation and synergistic fibrillization of tau and alpha-synuclein.

Authors:  Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

6.  Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects.

Authors:  Thomas Gasser
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

7.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

Review 8.  α-Synuclein and dopamine at the crossroads of Parkinson's disease.

Authors:  Lara Lourenço Venda; Stephanie J Cragg; Vladimir L Buchman; Richard Wade-Martins
Journal:  Trends Neurosci       Date:  2010-10-18       Impact factor: 13.837

9.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

10.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.

Authors:  Tim Bartels; Joanna G Choi; Dennis J Selkoe
Journal:  Nature       Date:  2011-08-14       Impact factor: 49.962

View more
  36 in total

1.  Silencing of SIAH1 in SH-SY5Y affects α-synuclein degradation pathway.

Authors:  Jing Xu; Xin-Zhi Zhang; Yong-Jin Zhang; Xiu-Ming Li; Zeng-Lin Cai; Xiao-Min Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder.

Authors:  Noa Lipstein; Nanda M Verhoeven-Duif; Francesco E Michelassi; Nathaniel Calloway; Peter M van Hasselt; Katarzyna Pienkowska; Gijs van Haaften; Mieke M van Haelst; Ron van Empelen; Inge Cuppen; Heleen C van Teeseling; Annemieke M V Evelein; Jacob A Vorstman; Sven Thoms; Olaf Jahn; Karen J Duran; Glen R Monroe; Timothy A Ryan; Holger Taschenberger; Jeremy S Dittman; Jeong-Seop Rhee; Gepke Visser; Judith J Jans; Nils Brose
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

3.  LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.

Authors:  Dan Hu; Jian-Yi Niu; Jing Xiong; Shu-Ke Nie; Fei Zeng; Zhao-Hui Zhang
Journal:  Curr Med Sci       Date:  2018-12-07

4.  Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein.

Authors:  Fang Yang; Ya-ping Yang; Cheng-jie Mao; Ling Liu; Hui-fen Zheng; Li-fang Hu; Chun-feng Liu
Journal:  Acta Pharmacol Sin       Date:  2013-04-22       Impact factor: 6.150

Review 5.  Protein Phosphatase 2A: a Double-Faced Phosphatase of Cellular System and Its Role in Neurodegenerative Disorders.

Authors:  Md Nematullah; M N Hoda; Farah Khan
Journal:  Mol Neurobiol       Date:  2017-02-21       Impact factor: 5.590

6.  Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease.

Authors:  Anelya Kh Alieva; Elena V Filatova; Anna A Kolacheva; Margarita M Rudenok; Petr A Slominsky; Mikhail V Ugrumov; Maria I Shadrina
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

7.  Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro.

Authors:  Paolo Ruzza; Giuliano Siligardi; Rohanah Hussain; Anna Marchiani; Mehmet Islami; Luigi Bubacco; Giovanna Delogu; Davide Fabbri; Maria A Dettori; Mario Sechi; Nicolino Pala; Ylenia Spissu; Rossana Migheli; Pier A Serra; GianPietro Sechi
Journal:  ACS Chem Neurosci       Date:  2013-10-24       Impact factor: 4.418

Review 8.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

9.  20C, a bibenzyl compound isolated from Gastrodia elata, protects PC12 cells against rotenone-induced apoptosis via activation of the Nrf2/ARE/HO-1 signaling pathway.

Authors:  Ju-Yang Huang; Yu-He Yuan; Jia-Qing Yan; Ya-Nan Wang; Shi-Feng Chu; Cheng-Gen Zhu; Qing-Lan Guo; Jian-Gong Shi; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

10.  Pulsed Hydrogen-Deuterium Exchange Illuminates the Aggregation Kinetics of α-Synuclein, the Causative Agent for Parkinson's Disease.

Authors:  Eva Illes-Toth; Don L Rempel; Michael L Gross
Journal:  ACS Chem Neurosci       Date:  2018-04-11       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.